BDTX — Black Diamond Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1701541 ·
Last close
$1.83
Market Cap
$104.86M
52W High
$4.94
52W Low
$1.60
ADV30
585,967
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,057,000 | -9,905,000 | 125,029,000 | 19,194,000 | 28,938,000 |
| Mar 2026 | 0 | — | -11,259,000 | -9,036,000 | 132,922,000 | 30,071,000 | 28,622,000 |
| Dec 2025 | 0 | — | -10,262,000 | -15,116,000 | 143,010,000 | 20,990,000 | 30,799,000 |
| Sep 2025 | 0 | — | -10,978,000 | -8,498,000 | 157,733,000 | 30,864,000 | 31,581,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-32,837,000
Investing CF
$22,077,000
Financing CF
$-30,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.75
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-483,681,000
Inventory
—
Receivables
—
ST Investments
$91,312,000
EBIT TTM
$-44,556,000
Pretax Income TTM
$-42,555,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-44,349,000
Free Cash Flow
$-23,577,500
Enterprise Value
$20,222,420
Total Cash
$110,506,000
Total Debt
$16,970,000
Shares Out
57,301,774
Trailing EPS
$-0.75
Book Value
$1.67
ROE
-37.2%
ROA
-19.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 70,000,000 | 19,870,000 | 22,367,000 | 143,010,000 | 30,799,000 | 112,211,000 | 29,614,000 |
| Dec 2024 | 0 | -78,781,000 | -69,676,000 | 122,640,000 | 39,355,000 | 83,285,000 | -62,303,000 |
| Dec 2023 | 0 | -86,460,000 | -82,442,000 | 158,567,000 | 41,831,000 | 116,736,000 | -66,717,000 |
| Dec 2022 | 0 | -92,828,000 | -91,169,000 | 156,255,000 | 40,560,000 | 115,695,000 | -85,082,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$70,000,000
NetIncome TTM
$-3,676,000
OpCashFlow TTM
$0
Assets (Latest)
$143,010,000
Forward EPS
$-1.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLLS | Cellectis S.A. | $107.62M | $1.48 | — |
| VXRT | Vaxart, Inc. | $110.41M | $0.45 | — |
| CRDF | Cardiff Oncology, Inc. | $93.35M | $1.20 | — |
| CGTX | COGNITION THERAPEUTICS INC | $89.24M | $0.94 | — |
| LENZ | LENZ Therapeutics, Inc. | $124.42M | $3.96 | — |
News headlines (Yahoo Finance, 1h cache)
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:01 · Yahoo
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-05 20:01 · Yahoo
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
2026-06-06 09:04 · Yahoo
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
2026-05-27 15:13 · Yahoo
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
2026-05-22 12:00 · Yahoo
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
2026-05-21 23:09 · Yahoo
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
2026-05-21 21:13 · Yahoo
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
2026-05-19 12:00 · Yahoo
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.